Purpose: To evaluate real-world implementation of long-acting injectable cabotegravir (CAB)-based regimens for HIV treatment and Pre-Exposure Prophylaxis (PrEP)assessing adherence, retention, and outcomes.
Methods: This retrospective study evaluated patients initiating long-acting cabotegravir (CAB) based injectable therapy at Temple University Health System in Philadelphia, PA between FDA approval and September 1st 2025. Primary endpoints were adherence (defined by injections received within the FDA-approved ±7-day window) and retention in care. Secondary endpoints included continued viral suppression (HIV RNA <200 copies/mL) in the treatment group and all-cause discontinuation across both groups.Demographics, comorbidities, prior antiretroviral regimens, and associated laboratory values were collected.
Results: 200 patients received CAB/RPV for HIVtreatment, median injections were 11 (5–16), and total injections given were 2121. 24 patients on CAB PrEP, median number of injections was 4.5 (3–11).In the treatment group, 45.5% of injections were within the ±7-day window; 67% required reinitiation (>30-day gaps). Overall, 72% remained on therapy. PrEP adherence was 79.2% within the window. At study end, 82.1% (46/56) of treatment discontinuations remained suppressed and 5.4% (3/56) had detectable HIV RNA; resistance occurred in 10.7%(6/56) of cases. Treatment discontinuation was 28%, driven by patient preference (28.6%) and
Graduated from Thomas Jefferson University in 2025. Currently a PGY-1 resident at Temple University Hospital and will continue there as a PGY-2 in Infectious Diseases.
